Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438

Article  CAS  PubMed  Google Scholar 

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical O (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796

Article  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Breast Cancer version 4.2023. National Comprehensive Cancer Network https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed August 4 2023.

Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993–2000

Article  CAS  PubMed  Google Scholar 

Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, Research UKCCoC, Ductal Carcinoma in situ Working P, Dcis trialists in the Uk A, New Z (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102

Article  PubMed  Google Scholar 

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12(1):21–29

Article  CAS  PubMed  Google Scholar 

Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488

Article  PubMed  PubMed Central  Google Scholar 

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrera M, Buttiron Webber T, Boni L, Bonanni B (2019) Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 37(19):1629–1637

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Serra P, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B, DeCensi A (2023) Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 Study. J Clin Oncol 41(17):3116–3121

Article  CAS  PubMed  Google Scholar 

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CA guideline update. J Clin Oncol 38(12):1346–1366

Article  PubMed  Google Scholar 

Anderson C, Meyer AM, Wheeler SB, Zhou L, Reeder-Hayes KE, Nichols HB (2017) Endocrine therapy initiation and medical oncologist utilization among women diagnosed with ductal carcinoma in situ. Oncologist 22(5):535–541

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson C, Winn AN, Dusetzina SB, Nichols HB (2017) Endocrine therapy initiation among older women with ductal carcinoma in situ. J Cancer Epidemiol 2017:6091709

Article  PubMed  PubMed Central  Google Scholar 

Madubata CC, Liu Y, Goodman MS, Yun S, Yu J, Lian M, Colditz GA (2016) Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race. Breast Cancer Res Treat 160(3):563–572

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nichols HB, Bowles EJ, Islam J, Madziwa L, Stürmer T, Tran DT, Buist DS (2016) Tamoxifen initiation after ductal carcinoma in situ. Oncologist 21(2):134–140

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao H, Hei N, Wu Y, Chan W, Lei X, Cameron C, Chang S, Chavez-MacGregor M, Giordano SH (2017) Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer 123(6):940–947

Article  CAS  PubMed  Google Scholar 

Flanagan MR, Rendi MH, Gadi VK, Calhoun KE, Gow KW, Javid SH (2015)Adjuvant endocrine therapy in patients with ductal carcinoma in situ: a population-based retrospective analysis from 2005 to 2012 in the National Cancer Data Base. Ann Surg Oncol 22(10):3264–3272

Article  PubMed  PubMed Central  Google Scholar 

Bowles EJA, Ramin C, Buist DSM, Feigelson HS, Weinmann S, Veiga LHS, Bodelon C, Curtis RE, Vo JB, Berrington de Gonzalez A, Gierach GL (2022) Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001–2016. Breast Cancer Res Treat 193(1):203–216

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feigelson HS, Bodelon C, Powers JD, Curtis RE, Buist DSM, Veiga LHS, Bowles EJA, Berrington de Gonzalez A, Gierach GL (2021) Body mass index and risk of second cancer among women with breast cancer. J Natl Cancer Inst 113(9):1156–1160

Article  PubMed  PubMed Central  Google Scholar 

Ramin C, Veiga LHS, Vo JB, Curtis RE, Bodelon C, Aiello Bowles EJ, Buist DSM, Weinmann S, Feigelson HS, Gierach GL, Berrington de Gonzalez A (2023) Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Res 25(1):50

Article  CAS  PubMed  PubMed Central  Google Scholar 

Estrogen Receptor (ER) Assay. https://staging.seer.cancer.gov/cs/input/02.05.50/breast/ssf1/?version=/tnm/home/1.5/. Accessed July 18 2024.

Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10021):849–856

Article  CAS  PubMed  Google Scholar 

Bedi JS, Mayo RM, Truong K, Chen L, Dickes L, Sherrill WW, Jones K (2018) Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women. Breast Cancer Res Treat 171(3):759–765

Article  CAS  PubMed  Google Scholar 

Halasz SR, O’Keefe T, Wallace AM, Blair SL (2021) Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes. Breast Cancer Res Treat 186(2):551–559

Article  CAS  PubMed  Google Scholar 

Levy J, Farag F, Cole J (2022) Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience. Breast Cancer Res Treat 196(1):207–213

Article  PubMed  PubMed Central  Google Scholar 

Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689

Article  CAS  PubMed  Google Scholar 

Livaudais JC, Hwang ES, Karliner L, Napoles A, Stewart S, Bloom J, Kaplan CP (2012) Adjuvant hormonal therapy use among women with ductal carcinoma in situ. J Womens Health (Larchmt) 21(1):35–42

Article  PubMed  Google Scholar 

Nakhlis F, Lazarus L, Hou N, Acharya S, Khan SA, Staradub VL, Rademaker AW, Morrow M (2005) Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg 201(5):688–694

Article  PubMed  Google Scholar 

Bailes AA, Kuerer HM, Lari SA, Jones LA, Brewster AM (2013) Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast. Cancer 119(1):150–157

Article  PubMed  Google Scholar 

Nguyen TT, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC (2017) Factors influencing use of hormone therapy for ductal carcinoma in situ: a national cancer database study. Ann Surg Oncol 24(10):2989–2998